Lilly's Lebrikizumab Shows Clinical Benefit In Late-Stage Atopic Eczema Trials

  • Eli Lilly And Co's LLY lebrikizumab ADvocate 1 and ADvocate 2 Phase 3 clinical trials met primary and all key secondary endpoints at Week 16
  • Lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis (AD) in the two Phase 3 trials.
  • Results demonstrated that more than half of the patients achieved at least 75% clearance to total clearance on lebrikizumab monotherapy.
  • Lebrikizumab is a novel monoclonal antibody (mAb) that binds soluble IL-13 with high affinity, has high bioavailability, has a long half-life, and blocks IL-13 signaling.
  • The FDA has granted Fast Track designation to lebrikizumab.
  • The full study results from ADvocate 1 and ADvocate 2 will be disclosed at future congresses in 2022.
  • The most common adverse events included conjunctivitis, nasopharyngitis, and headache for lebrikizumab-treated patients.
  • Discontinuations due to adverse events were similar in the lebrikizumab group (1.4%) compared to placebo (1.7%).
  • Price Action: LLY shares closed at $264.21 on Friday.

Posted In: atopic dermatitisBriefsPhase 3 TrialBiotechNewsHealth CareGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.